Surgical Research Center, Institute of Urology, School of Medicine, Southeast University, Nanjing, China.
Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, China.
Pathol Oncol Res. 2021 Mar 30;27:610360. doi: 10.3389/pore.2021.610360. eCollection 2021.
Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) is a rare subtype of renal cell carcinoma (RCC), characterized by translocations of Xp11.2 breakpoints, involving of the transcription factor three gene (TFE3). The aim of our study was to comprehensively characterize the clinical characteristics and outcomes, and to identify risk factors associated with OS and PFS in Xp11.2 tRCC patients. Literature search on Xp11.2 tRCC was performed using databases such as pubmed EMBASE and Web of Science. Studies were eligible if outcomes data (OS and/or PFS) were reported for patients with a histopathologically confirmed Xp11.2 tRCC. PFS and OS were evaluated using the univariable and multivariable Cox regression model. There were 80 eligible publications, contributing 415 patients. In multivariable analyses, the T stage at presentation was significantly associated with PFS (HR: 3.87; 95% CI: 1.70 to 8.84; = 0.001). The median time of PFS was 72 months. In the multivariable analyses, age at diagnosis (HR: 2.16; 95% CI: 1.03 to 4.50; = 0.041), T stage at presentation (HR: 4.44; 95% CI: 2.16 to 9.09; < 0.001) and metastasis status at presentation (HR: 2.67; 95% CI: 1.12 to 6.41; = 0.027) were all associated with OS, with a median follow-up time of 198 months. T stage at presentation is the only factor that is associated with both PFS and OS in patients with Xp11.2 tRCC. Also, patients over 45 or with metastases are more likely to have poorer OS.
Xp11.2 易位性肾细胞癌（Xp11.2 tRCC）是一种罕见的肾细胞癌（RCC）亚型，其特征在于 Xp11.2 断点的易位，涉及转录因子三基因（TFE3）。我们的研究旨在全面描述 Xp11.2 tRCC 患者的临床特征和结局，并确定与 OS 和 PFS 相关的危险因素。使用 pubmed EMBASE 和 Web of Science 等数据库对 Xp11.2 tRCC 的文献进行了检索。如果有组织病理学证实的 Xp11.2 tRCC 患者的结局数据（OS 和/或 PFS）报告，则研究符合条件。使用单变量和多变量 Cox 回归模型评估 PFS 和 OS。共有 80 项符合条件的出版物，为 415 名患者提供了数据。在多变量分析中，就诊时的 T 分期与 PFS 显著相关（HR：3.87；95%CI：1.70 至 8.84； = 0.001）。PFS 的中位时间为 72 个月。在多变量分析中，诊断时的年龄（HR：2.16；95%CI：1.03 至 4.50； = 0.041）、就诊时的 T 分期（HR：4.44；95%CI：2.16 至 9.09； < 0.001）和就诊时的转移状态（HR：2.67；95%CI：1.12 至 6.41； = 0.027）均与 OS 相关，中位随访时间为 198 个月。就诊时的 T 分期是唯一与 Xp11.2 tRCC 患者的 PFS 和 OS 均相关的因素。此外，45 岁以上或有转移的患者更有可能出现较差的 OS。
